Mumbai, September 16 (Patrika English News). Shares of Zydus Lifesciences edged higher on Tuesday after its step-down wholly owned subsidiary, ZyVet Animal Health, launched the first FDA-approved generic of phenylpropanolamine hydrochloride tablets in the United States.
The stock opened at ₹1,037.35 on the BSE and touched a high of ₹1,043.35 before trading at ₹1,038.35, up by ₹1.65 or 0.16% from the previous close. Around 9,063 shares were exchanged during the session. The company’s market capitalisation stands at ₹1.04 lakh crore.
The newly launched product is used to manage urinary incontinence in dogs caused by urethral sphincter hypotonus, a condition commonly seen in spayed females and aging dogs. ZyVet’s generic version offers reliable symptom relief at a lower cost, with multiple dosage strengths for precise treatment.
The company said this launch highlights ZyVet’s commitment to providing trusted, affordable, and high-quality therapies to veterinary professionals across the US. It also reinforces that generic animal health products are as effective as branded ones.
ZyVet, a subsidiary of Zydus Pharmaceuticals (USA) Inc. and part of Zydus Lifesciences, continues to expand its product portfolio rapidly, supported by Zydus’s decades of pharmaceutical R&D, regulatory, and manufacturing expertise.
Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company with operations spanning research, development, production, and distribution of medicines globally.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
